<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593450</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-137</org_study_id>
    <secondary_id>U10EY017823</secondary_id>
    <nct_id>NCT00593450</nct_id>
  </id_info>
  <brief_title>Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial</brief_title>
  <official_title>Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the relative efficacy and safety of treatment of
      neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a
      variable schedule, and Avastin on a variable schedule.

      A five year follow-up visit is being conducted in 2014 to gather information on long term
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age related macular degeneration (AMD) is the leading cause of severe vision loss in people
      over the age of 65 in the United States and other Western countries. More than 1.6 million
      people in the US currently have one or both eyes affected by the advanced stage of AMD.

      Lucentis® is the most effective treatment for neovascular AMD studied to date. Bevacizumab
      (Avastin®) and Lucentis® are derived from the same monoclonal antibody. Following the
      encouraging clinical trial results with Lucentis®, several investigators began evaluating
      intravitreal Avastin® for the treatment of CNV. Given its molecular similarity to Lucentis,
      its low cost, and its availability, the interest in Avastin® has been considerable. Avastin®
      has not been evaluated relative to Lucentis®.

      In addition, previous studies do not answer the question of whether a reduced dosing schedule
      is as effective as a fixed schedule of monthly injections. Treatment dependent on clinical
      response has the potential to reduce the treatment burden to patients as well as to reduce
      the overall cost of therapy.

      Only a single eye in each patient was analyzed.

      At the five year follow-up visit, the subjects will undergo the same examinations and
      procedures as in the original study; however, the five year follow-up visit deos not involve
      any study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2008</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Visual-acuity Score (Continuous)</measure>
    <time_frame>Baseline and 1 Year</time_frame>
    <description>Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.
In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Visual-acuity Score (Frequency)</measure>
    <time_frame>Baseline and 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual-acuity Score and Snellen Equivalent (Frequency)</measure>
    <time_frame>at 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual-acuity Score and Snellen Equivalent (Continuous)</measure>
    <time_frame>at 1 Year</time_frame>
    <description>Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.
In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatments</measure>
    <time_frame>1 Year</time_frame>
    <description>Cumulative over the 1 year of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Cost of Drug/Patient</measure>
    <time_frame>at 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Thickness at Fovea</measure>
    <time_frame>at 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Thickness Change From Baseline at Fovea</measure>
    <time_frame>Baseline and 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea</measure>
    <time_frame>at 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea</measure>
    <time_frame>Baseline and 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid on Optical Coherence Tomography</measure>
    <time_frame>at 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dye Leakage on Angiogram</measure>
    <time_frame>at 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Lesion</measure>
    <time_frame>at 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Lesion Change From Baseline</measure>
    <time_frame>Baseline and 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline</measure>
    <time_frame>Baseline and 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure From Baseline</measure>
    <time_frame>Baseline and 1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1208</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>• 0.5 mg (0.05 mL)intravitreal injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>• 1.25 mg (0.05 mL)intravitreal injection</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active, subfoveal choroidal neovascularization (CNV)

          -  Fibrosis &lt; 50% of total lesion area

          -  Visual acuity (VA) 20/25-20/320

          -  Age ≥ 50 yrs

          -  At least 1 drusen (&gt;63μ) in either eye or late AMD in fellow eye

        Exclusion Criteria:

          -  Previous treatment for CNV in study eye

          -  Other progressive retinal disease likely to compromise VA

          -  Contraindications to injections with Lucentis or Avastin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel F Martin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart L Fine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Study Vice-Chair, University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maureen G Maguire, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director of Coordinating Center, University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenn Jaffe,, MD</last_name>
    <role>Study Director</role>
    <affiliation>Director of OCT Reading Center, Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan E Grunwald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator of Photography Reading Center, Universisty of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Consultants of Arizona</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates Southwest, P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group, Inc.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Retina Medical Group, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retinal Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Retina Medical Group, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of Florida</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Flossmoor</city>
        <state>Illinois</state>
        <zip>60422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital/Illinois Retina Associates</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville School of Medicine</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elman Retina Group, P.A.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Group of Washington</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialists</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye &amp; Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Vanguard Medical Associates</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Research Foundation/Associated Retinal Consultants, P.C.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Research Foundation/Associated Retinal Consultants, P.C.</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision research Foundation/Associated Retinal Consultants. P.C.</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VitreoRetinal Surgery</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Center, PA</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Center, PA</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Riverhead</city>
        <state>New York</state>
        <zip>11902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, nose &amp; Throat Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye,Ear, Nose &amp; Throat Associates</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Eye Physicians &amp; Surgeons-Retina Division</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland, Inc.</name>
      <address>
        <city>Lakewood</city>
        <state>Ohio</state>
        <zip>44107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean A. McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Diagnostic and Treatment Associates, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Consultants</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>38909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates, P.C.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Vitreous of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Group of Washington</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.upenn.edu/cpob/catt.html</url>
    <description>Click here for more information about this study: Comparison of AMD Treatments Trials (CATT)</description>
  </link>
  <link>
    <url>http://www.nei.nih.gov/health/clinicalstudies/</url>
    <description>NEI Clinical Studies Database</description>
  </link>
  <reference>
    <citation>Martin DF, Maguire MG, Fine SL. Identifying and eliminating the roadblocks to comparative-effectiveness research. N Engl J Med. 2010 Jul 8;363(2):105-7. doi: 10.1056/NEJMp1001201. Epub 2010 Jun 2.</citation>
    <PMID>20519677</PMID>
  </reference>
  <results_reference>
    <citation>CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.</citation>
    <PMID>21526923</PMID>
  </results_reference>
  <results_reference>
    <citation>Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.</citation>
    <PMID>22555112</PMID>
  </results_reference>
  <results_reference>
    <citation>Grunwald JE, Daniel E, Ying GS, Pistilli M, Maguire MG, Alexander J, Whittock-Martin R, Parker CR, Sepielli K, Blodi BA, Martin DF; CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2012 Aug;119(8):1634-41. doi: 10.1016/j.ophtha.2012.02.013. Epub 2012 Apr 17.</citation>
    <PMID>22512984</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin DF, Maguire MG, Fine SL. Bevacizumab: not as good with more adverse reactions? Response. Clin Exp Ophthalmol. 2011 Sep-Oct;39(7):718-20. doi: 10.1111/j.1442-9071.2011.02703.x.</citation>
    <PMID>22452699</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin DF, Maguire MG, Fine SL. Ranibizumab and bevacizumab for AMD. Authors reply. N Engl J Med 2011; 365:2237</citation>
  </results_reference>
  <results_reference>
    <citation>DeCroos FC, Toth CA, Stinnett SS, Heydary CS, Burns R, Jaffe GJ; CATT Research Group. Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2012 Dec;119(12):2549-57. doi: 10.1016/j.ophtha.2012.06.040. Epub 2012 Aug 28.</citation>
    <PMID>22939114</PMID>
  </results_reference>
  <results_reference>
    <citation>Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.</citation>
    <PMID>23047002</PMID>
  </results_reference>
  <results_reference>
    <citation>Hagstrom SA, Ying GS, Pauer GJT, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2013 Mar;120(3):593-599. doi: 10.1016/j.ophtha.2012.11.037. Epub 2013 Jan 18.</citation>
    <PMID>23337555</PMID>
  </results_reference>
  <results_reference>
    <citation>Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Sep;120(9):1860-70. doi: 10.1016/j.ophtha.2013.01.073. Epub 2013 May 1.</citation>
    <PMID>23642377</PMID>
  </results_reference>
  <results_reference>
    <citation>Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group). Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/j.ophtha.2013.03.017. Epub 2013 May 22.</citation>
    <PMID>23706946</PMID>
  </results_reference>
  <results_reference>
    <citation>Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014 Mar;121(3):656-66. doi: 10.1016/j.ophtha.2013.10.019. Epub 2013 Dec 4.</citation>
    <PMID>24314839</PMID>
  </results_reference>
  <results_reference>
    <citation>Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014 Jan;121(1):150-61. doi: 10.1016/j.ophtha.2013.08.015. Epub 2013 Sep 29.</citation>
    <PMID>24084496</PMID>
  </results_reference>
  <results_reference>
    <citation>Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7.</citation>
    <PMID>24652518</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. doi: 10.1016/j.ajo.2014.04.004. Epub 2014 Apr 13.</citation>
    <PMID>24727261</PMID>
  </results_reference>
  <results_reference>
    <citation>Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014 Oct;121(10):1956-65. doi: 10.1016/j.ophtha.2014.04.020. Epub 2014 May 15.</citation>
    <PMID>24835760</PMID>
  </results_reference>
  <results_reference>
    <citation>Ying GS, Kim BJ, Maguire MG, Huang J, Daniel E, Jaffe GJ, Grunwald JE, Blinder KJ, Flaxel CJ, Rahhal F, Regillo C, Martin DF; CATT Research Group. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol. 2014 Aug;132(8):915-21. doi: 10.1001/jamaophthalmol.2014.1019.</citation>
    <PMID>24875610</PMID>
  </results_reference>
  <results_reference>
    <citation>Gewaily DY, Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Ostroff CP, Fine SL; CATT Research Group. Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Sep;158(3):525-31.e2. doi: 10.1016/j.ajo.2014.06.004. Epub 2014 Jun 17.</citation>
    <PMID>24949820</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JY, Folgar FA, Maguire MG, Ying GS, Toth CA, Martin DF, Jaffe GJ; CATT Research Group. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2014 Dec;121(12):2423-31. doi: 10.1016/j.ophtha.2014.06.013. Epub 2014 Jul 23.</citation>
    <PMID>25064723</PMID>
  </results_reference>
  <results_reference>
    <citation>Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014 Sep 15;(9):CD011230. doi: 10.1002/14651858.CD011230.pub2. Review.</citation>
    <PMID>25220133</PMID>
  </results_reference>
  <results_reference>
    <citation>Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group. Outcomes of eyes with lesions composed of &gt;50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2015 Feb;122(2):391-398.e5. doi: 10.1016/j.ophtha.2014.08.020. Epub 2014 Oct 11.</citation>
    <PMID>25307130</PMID>
  </results_reference>
  <results_reference>
    <citation>Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015 Apr;122(4):809-16. doi: 10.1016/j.ophtha.2014.11.007. Epub 2014 Dec 24.</citation>
    <PMID>25542520</PMID>
  </results_reference>
  <results_reference>
    <citation>Meredith TA, McCannel CA, Barr C, Doft BH, Peskin E, Maguire MG, Martin DF, Prenner JL; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2015 Apr;122(4):817-21. doi: 10.1016/j.ophtha.2014.10.027. Epub 2015 Jan 15.</citation>
    <PMID>25600198</PMID>
  </results_reference>
  <results_reference>
    <citation>Toth CA, Decroos FC, Ying GS, Stinnett SS, Heydary CS, Burns R, Maguire M, Martin D, Jaffe GJ. IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. Retina. 2015 Jul;35(7):1303-14. doi: 10.1097/IAE.0000000000000483.</citation>
    <PMID>26102433</PMID>
  </results_reference>
  <results_reference>
    <citation>Ciulla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, Daniel E, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2015 Jun;122(6):1203-11. doi: 10.1016/j.ophtha.2015.02.031. Epub 2015 Mar 29. Erratum in: Ophthalmology. 2015 Aug;122(8):1733. Cuilla, Thomas A [Corrected to Ciulla, Thomas A].</citation>
    <PMID>25824327</PMID>
  </results_reference>
  <results_reference>
    <citation>Hagstrom SA, Ying GS, Maguire MG, Martin DF; CATT Research Group, Gibson J, Lotery A, Chakravarthy U; IVAN Study Investigators. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology. 2015 Aug;122(8):1563-8. doi: 10.1016/j.ophtha.2015.04.024. Epub 2015 May 28.</citation>
    <PMID>26028346</PMID>
  </results_reference>
  <results_reference>
    <citation>Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2015 Sep;122(9):1846-53.e5. doi: 10.1016/j.ophtha.2015.05.042. Epub 2015 Jul 2.</citation>
    <PMID>26143666</PMID>
  </results_reference>
  <results_reference>
    <citation>Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA, Huang J, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015 Dec;122(12):2523-31.e1. doi: 10.1016/j.ophtha.2015.08.015. Epub 2015 Sep 15.</citation>
    <PMID>26383996</PMID>
  </results_reference>
  <results_reference>
    <citation>Ying GS, Maguire MG, Daniel E, Grunwald JE, Ahmed O, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Feb;123(2):352-60. doi: 10.1016/j.ophtha.2015.09.046. Epub 2015 Nov 4.</citation>
    <PMID>26545320</PMID>
  </results_reference>
  <results_reference>
    <citation>Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2016 Mar;123(3):609-16. doi: 10.1016/j.ophtha.2015.10.034. Epub 2015 Dec 8.</citation>
    <PMID>26681392</PMID>
  </results_reference>
  <results_reference>
    <citation>Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Apr;123(4):858-64. doi: 10.1016/j.ophtha.2015.11.030. Epub 2016 Jan 8.</citation>
    <PMID>26778329</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Apr;123(4):865-75. doi: 10.1016/j.ophtha.2015.12.002. Epub 2016 Jan 9.</citation>
    <PMID>26783095</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou Q, Daniel E, Maguire MG, Grunwald JE, Martin ER, Martin DF, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Jul;123(7):1530-40. doi: 10.1016/j.ophtha.2016.02.043. Epub 2016 Apr 1.</citation>
    <PMID>27040149</PMID>
  </results_reference>
  <results_reference>
    <citation>Maguire MG, Ying GS, Jaffe GJ, Toth CA, Daniel E, Grunwald J, Martin DF, Hagstrom SA; CATT Research Group. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. 2016 Jun 1;134(6):674-81. doi: 10.1001/jamaophthalmol.2016.0669.</citation>
    <PMID>27099955</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>June 18, 2012</results_first_submitted>
  <results_first_submitted_qc>August 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2012</results_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>choroidal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Available at https://hyperprod.cceb.med.upenn.edu/catt/catt_index.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Note: The Data and Safety Monitoring Committee for CATT recommended excluding the data for all patients (N=23) from one center because of serious protocol non-compliance. Unless specified otherwise, only the 1185 patients enrolled by the remaining 43 centers are included in analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1-Lucentis Monthly</title>
          <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
        </group>
        <group group_id="P2">
          <title>2-Avastin Monthly</title>
          <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
        </group>
        <group group_id="P3">
          <title>3-Lucentis as Needed</title>
          <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
        </group>
        <group group_id="P4">
          <title>4-Avastin as Needed</title>
          <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="286"/>
                <participants group_id="P3" count="298"/>
                <participants group_id="P4" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
                <participants group_id="P2" count="265"/>
                <participants group_id="P3" count="285"/>
                <participants group_id="P4" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1-Lucentis Monthly</title>
          <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
        </group>
        <group group_id="B2">
          <title>2-Avastin Monthly</title>
          <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
        </group>
        <group group_id="B3">
          <title>3-Lucentis as Needed</title>
          <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
        </group>
        <group group_id="B4">
          <title>4-Avastin as Needed</title>
          <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="301"/>
            <count group_id="B2" value="286"/>
            <count group_id="B3" value="298"/>
            <count group_id="B4" value="300"/>
            <count group_id="B5" value="1185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.2" spread="7.4"/>
                    <measurement group_id="B2" value="80.1" spread="7.3"/>
                    <measurement group_id="B3" value="78.4" spread="7.8"/>
                    <measurement group_id="B4" value="79.3" spread="7.6"/>
                    <measurement group_id="B5" value="79.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="103"/>
                    <measurement group_id="B5" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="142"/>
                    <measurement group_id="B5" value="560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=90 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="184"/>
                    <measurement group_id="B5" value="732"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="296"/>
                    <measurement group_id="B4" value="294"/>
                    <measurement group_id="B5" value="1168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of myocardial infarction</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="268"/>
                    <measurement group_id="B4" value="264"/>
                    <measurement group_id="B5" value="1045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of stroke</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="276"/>
                    <measurement group_id="B4" value="284"/>
                    <measurement group_id="B5" value="1115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of transient ischemic attack</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="289"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="286"/>
                    <measurement group_id="B4" value="281"/>
                    <measurement group_id="B5" value="1117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134" spread="18"/>
                    <measurement group_id="B2" value="135" spread="19"/>
                    <measurement group_id="B3" value="136" spread="17"/>
                    <measurement group_id="B4" value="135" spread="17"/>
                    <measurement group_id="B5" value="135" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="10"/>
                    <measurement group_id="B2" value="75" spread="10"/>
                    <measurement group_id="B3" value="76" spread="9"/>
                    <measurement group_id="B4" value="75" spread="10"/>
                    <measurement group_id="B5" value="75" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual-acuity score and Snellen equivalent</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>68-82 letters, 20/25-40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="103"/>
                    <measurement group_id="B5" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>53-67 letters, 20/50-80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>38-52 letters, 20/100-160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23-37 letters, 20/200-320</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual-acuity score and Snellen equivalent</title>
          <description>Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.
In this study, the visual acuity letter score is ranged from 23 to 82, with the higher score the better visual acuity.</description>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="14.3"/>
                    <measurement group_id="B2" value="60.2" spread="13.1"/>
                    <measurement group_id="B3" value="61.5" spread="13.2"/>
                    <measurement group_id="B4" value="60.4" spread="13.4"/>
                    <measurement group_id="B5" value="60.5" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total thickness at fovea</title>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="458" spread="184"/>
                    <measurement group_id="B2" value="463" spread="196"/>
                    <measurement group_id="B3" value="458" spread="193"/>
                    <measurement group_id="B4" value="461" spread="175"/>
                    <measurement group_id="B5" value="460" spread="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Retinal thickness plus subfoveal-fluid thickness at fovea</title>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251" spread="122"/>
                    <measurement group_id="B2" value="254" spread="121"/>
                    <measurement group_id="B3" value="247" spread="122"/>
                    <measurement group_id="B4" value="252" spread="115"/>
                    <measurement group_id="B5" value="251" spread="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Foveal center involvement</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Choroidal neovacularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="183"/>
                    <measurement group_id="B5" value="688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No choroidal neovascularization or can't grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Visual-acuity Score (Frequency)</title>
        <time_frame>Baseline and 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Visual-acuity Score (Frequency)</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increase of ≥15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase of 5-14 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change of ≤4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease of 5-14 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease of ≥15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual-acuity Score (Continuous)</title>
        <description>Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.
In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement.</description>
        <time_frame>Baseline and 1 Year</time_frame>
        <population>All patients who had VA measured at week 52 were included in the analysis. All analyses were performed on the basis of the intention-to-treat principle. The Data and Safety Monitoring Committee recommended that data for all 23 patients at one center be excluded because of serious protocol noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual-acuity Score (Continuous)</title>
          <description>Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.
In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement.</description>
          <population>All patients who had VA measured at week 52 were included in the analysis. All analyses were performed on the basis of the intention-to-treat principle. The Data and Safety Monitoring Committee recommended that data for all 23 patients at one center be excluded because of serious protocol noncompliance.</population>
          <units>No. of Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="14.1"/>
                    <measurement group_id="O2" value="8.0" spread="15.8"/>
                    <measurement group_id="O3" value="6.8" spread="13.1"/>
                    <measurement group_id="O4" value="5.9" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was designed as a non-inferiority trial among four study groups, with the ability to test for superiority if a treatment was found to be non-inferior. Assuming a standard deviation for changes in visual acuity for 15 letters, we determined that a sample of 277 patients per group (which was increased to 300 to allow for a rate of death or dropout of 8%) would provide a power of 90%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority limit for the difference between study groups in the mean change in visual acuity at 1 year was 5 letters (i.e., one line on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual-acuity chart)</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>This p-value is for the test of overall difference among 4 treatment groups. The p-value for pairwise comparison was not performed, because this is a non-inferiority trial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We calcularted of two-sided 99.2% confidence intervals. We used Bonferroni approach to accommodate six pairwise treatment comparisons.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>99.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
            <estimate_desc>Estimate = Mean VA Change in Avastin Monthly Group - Mean VA Change in Lucentis Monthly Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The study was designed as a non-inferiority trial among four study groups, with the ability to test for superiority if a treatment was found to be non-inferior. Assuming a standard deviation for changes in visual acuity for 15 letters, we determined that a sample of 277 patients per group (which was increased to 300 to allow for a rate of death or dropout of 8%) would provide a power of 90%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority limit for the difference between study groups in the mean change in visual acuity at 1 year was 5 letters (i.e., one line on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual-acuity chart)</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>This p-value is for the test of overall difference among 4 treatment groups. The p-value for pairwise comparison was not performed, because this is a non-inferiority trial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We calcularted of two-sided 99.2% confidence intervals. We used Bonferroni approach to accommodate six pairwise treatment comparisons.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>99.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Estimate = Mean VA Change in Avastin as Needed Group - Mean VA Change in Lucentis as Needed Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study was designed as a non-inferiority trial among four study groups, with the ability to test for superiority if a treatment was found to be non-inferior. Assuming a standard deviation for changes in visual acuity for 15 letters, we determined that a sample of 277 patients per group (which was increased to 300 to allow for a rate of death or dropout of 8%) would provide a power of 90%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority limit for the difference between study groups in the mean change in visual acuity at 1 year was 5 letters (i.e., one line on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual-acuity chart)</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>This p-value is for the test of overall difference among 4 treatment groups. The p-value for pairwise comparison was not performed, because this is a non-inferiority trial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We calcularted of two-sided 99.2% confidence intervals. We used Bonferroni approach to accommodate six pairwise treatment comparisons.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>99.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Estimate = Mean VA Change in Lucentis as Needed Group - Mean VA Change in Lucentis Monthly Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The study was designed as a non-inferiority trial among four study groups, with the ability to test for superiority if a treatment was found to be non-inferior. Assuming a standard deviation for changes in visual acuity for 15 letters, we determined that a sample of 277 patients per group (which was increased to 300 to allow for a rate of death or dropout of 8%) would provide a power of 90%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority limit for the difference between study groups in the mean change in visual acuity at 1 year was 5 letters (i.e., one line on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual-acuity chart)</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>This p-value is for the test of overall difference among 4 treatment groups. The p-value for pairwise comparison was not performed, because this is a non-inferiority trial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We calcularted of two-sided 99.2% confidence intervals. We used Bonferroni approach to accommodate six pairwise treatment comparisons.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.9</dispersion_value>
            <ci_percent>99.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Estimate = Mean VA Change in Avastin as Needed Group - Mean VA Change in Avastin Monthly Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study was designed as a non-inferiority trial among four study groups, with the ability to test for superiority if a treatment was found to be non-inferior. Assuming a standard deviation for changes in visual acuity for 15 letters, we determined that a sample of 277 patients per group (which was increased to 300 to allow for a rate of death or dropout of 8%) would provide a power of 90%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority limit for the difference between study groups in the mean change in visual acuity at 1 year was 5 letters (i.e., one line on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual-acuity chart)</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>This p-value is for the test of overall difference among 4 treatment groups. The p-value for pairwise comparison was not performed, because this is a non-inferiority trial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We calcularted of two-sided 99.2% confidence intervals. We used Bonferroni approach to accommodate six pairwise treatment comparisons.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>99.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <estimate_desc>Estimate = Mean VA Change in Lucentis as Needed Group - Mean VA Change in Avastin Monthly Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The study was designed as a non-inferiority trial among four study groups, with the ability to test for superiority if a treatment was found to be non-inferior. Assuming a standard deviation for changes in visual acuity for 15 letters, we determined that a sample of 277 patients per group (which was increased to 300 to allow for a rate of death or dropout of 8%) would provide a power of 90%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority limit for the difference between study groups in the mean change in visual acuity at 1 year was 5 letters (i.e., one line on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual-acuity chart)</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>This p-value is for the test of overall difference among 4 treatment groups. The p-value for pairwise comparison was not performed, because this is a non-inferiority trial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We calcularted of two-sided 99.2% confidence intervals. We used Bonferroni approach to accommodate six pairwise treatment comparisons.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>99.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Estimate = Mean VA Change in Avastin as Needed Group - Mean VA Change in Lucentis Monthly Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual-acuity Score and Snellen Equivalent (Frequency)</title>
        <time_frame>at 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual-acuity Score and Snellen Equivalent (Frequency)</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>83-97 letters, 20/12-20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68-82 letters, 20/25-40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="141"/>
                    <measurement group_id="O4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>53-67 letters, 20/50-80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>38-52 letters, 20/100-160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤37 letters, ≤20/200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual-acuity Score and Snellen Equivalent (Continuous)</title>
        <description>Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.
In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity.</description>
        <time_frame>at 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual-acuity Score and Snellen Equivalent (Continuous)</title>
          <description>Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.
In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity.</description>
          <units>No. of Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="17.7"/>
                    <measurement group_id="O2" value="68.4" spread="18.2"/>
                    <measurement group_id="O3" value="68.4" spread="16.4"/>
                    <measurement group_id="O4" value="66.5" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatments</title>
        <description>Cumulative over the 1 year of trial</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatments</title>
          <description>Cumulative over the 1 year of trial</description>
          <units>Number of Treatments</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="1.5"/>
                    <measurement group_id="O2" value="11.9" spread="1.2"/>
                    <measurement group_id="O3" value="6.9" spread="3.0"/>
                    <measurement group_id="O4" value="7.7" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Cost of Drug/Patient</title>
        <time_frame>at 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Cost of Drug/Patient</title>
          <units>US dollars per patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23400" spread="3000"/>
                    <measurement group_id="O2" value="595" spread="60"/>
                    <measurement group_id="O3" value="13800" spread="6000"/>
                    <measurement group_id="O4" value="385" spread="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Thickness at Fovea</title>
        <time_frame>at 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Thickness at Fovea</title>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="281"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" spread="125"/>
                    <measurement group_id="O2" value="300" spread="149"/>
                    <measurement group_id="O3" value="294" spread="139"/>
                    <measurement group_id="O4" value="308" spread="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Thickness Change From Baseline at Fovea</title>
        <time_frame>Baseline and 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Thickness Change From Baseline at Fovea</title>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="260"/>
                <count group_id="O3" value="278"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-196" spread="176"/>
                    <measurement group_id="O2" value="-164" spread="181"/>
                    <measurement group_id="O3" value="-168" spread="186"/>
                    <measurement group_id="O4" value="-152" spread="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea</title>
        <time_frame>at 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea</title>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="281"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" spread="57"/>
                    <measurement group_id="O2" value="172" spread="81"/>
                    <measurement group_id="O3" value="166" spread="66"/>
                    <measurement group_id="O4" value="172" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea</title>
        <time_frame>Baseline and 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea</title>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="260"/>
                <count group_id="O3" value="278"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-100" spread="130"/>
                    <measurement group_id="O2" value="-79" spread="132"/>
                    <measurement group_id="O3" value="-81" spread="134"/>
                    <measurement group_id="O4" value="-79" spread="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid on Optical Coherence Tomography</title>
        <time_frame>at 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid on Optical Coherence Tomography</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="203"/>
                    <measurement group_id="O4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dye Leakage on Angiogram</title>
        <time_frame>at 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Dye Leakage on Angiogram</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="133"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="137"/>
                    <measurement group_id="O4" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of Lesion</title>
        <time_frame>at 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Area of Lesion</title>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="265"/>
                <count group_id="O4" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="6.8"/>
                    <measurement group_id="O2" value="6.5" spread="6.7"/>
                    <measurement group_id="O3" value="7.3" spread="6.5"/>
                    <measurement group_id="O4" value="7.0" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of Lesion Change From Baseline</title>
        <time_frame>Baseline and 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Area of Lesion Change From Baseline</title>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="5.2"/>
                    <measurement group_id="O2" value="0.3" spread="4.9"/>
                    <measurement group_id="O3" value="0.6" spread="6.2"/>
                    <measurement group_id="O4" value="1.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure From Baseline</title>
        <time_frame>Baseline and 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="250"/>
                <count group_id="O4" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="22.4"/>
                    <measurement group_id="O2" value="-5.4" spread="18.2"/>
                    <measurement group_id="O3" value="-5.2" spread="20.3"/>
                    <measurement group_id="O4" value="-4.5" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure From Baseline</title>
        <time_frame>Baseline and 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Lucentis Monthly</title>
            <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O2">
            <title>2-Avastin Monthly</title>
            <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
          </group>
          <group group_id="O3">
            <title>3-Lucentis as Needed</title>
            <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
          <group group_id="O4">
            <title>4-Avastin as Needed</title>
            <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure From Baseline</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="250"/>
                <count group_id="O4" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="11.9"/>
                    <measurement group_id="O2" value="-1.4" spread="11.2"/>
                    <measurement group_id="O3" value="-1.9" spread="10.2"/>
                    <measurement group_id="O4" value="-2.1" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at 1 year.</time_frame>
      <desc>Adverse events were ascertained through monthly questioning of patients by study coordinators who were aware of study-group assignments; events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) system, version 10. A medical monitor who was unaware of study-group assignments reviewed serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>1-Lucentis Monthly</title>
          <description>Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.</description>
        </group>
        <group group_id="E2">
          <title>2-Avastin Monthly</title>
          <description>Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.</description>
        </group>
        <group group_id="E3">
          <title>3-Lucentis as Needed</title>
          <description>Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
        </group>
        <group group_id="E4">
          <title>4-Avastin as Needed</title>
          <description>Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Death from vascular causes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Venous thrombotic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Nonfatal myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Nonfatal stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any other system organ class</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Death from any cause</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury or procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benignor malignant neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical or medical procedure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pseudoendophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Dr. Grunwald reports receiving consulting fees from GlaxoSmithKline; and Dr. Jaffe, consulting fees from Neurotech and SurModics. No other potential conflict of interest relevant to this article was reported.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Maureen Maguire</name_or_title>
      <organization>CATT Research Group</organization>
      <phone>215-615-1501</phone>
      <email>maguirem@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

